T. Wilt, T. Shamliyan, A. Shaukat, B. Taylor, R. MacDonald, Jian-Min Yuan, James R. Johnson, J. Tacklind, I. Rutks, R. Kane
{"title":"慢性乙型肝炎的管理","authors":"T. Wilt, T. Shamliyan, A. Shaukat, B. Taylor, R. MacDonald, Jian-Min Yuan, James R. Johnson, J. Tacklind, I. Rutks, R. Kane","doi":"10.1159/000322457","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis B affects 400 million people worldwide. The criteria for initiating and stopping treatment are still under debate in spite of well-established agents for its treatment. Hepatitis B v","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":"1 1","pages":"1-671"},"PeriodicalIF":0.0000,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Management of chronic hepatitis B\",\"authors\":\"T. Wilt, T. Shamliyan, A. Shaukat, B. Taylor, R. MacDonald, Jian-Min Yuan, James R. Johnson, J. Tacklind, I. Rutks, R. Kane\",\"doi\":\"10.1159/000322457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic hepatitis B affects 400 million people worldwide. The criteria for initiating and stopping treatment are still under debate in spite of well-established agents for its treatment. Hepatitis B v\",\"PeriodicalId\":72991,\"journal\":{\"name\":\"Evidence report/technology assessment\",\"volume\":\"1 1\",\"pages\":\"1-671\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence report/technology assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000322457\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence report/technology assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000322457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chronic hepatitis B affects 400 million people worldwide. The criteria for initiating and stopping treatment are still under debate in spite of well-established agents for its treatment. Hepatitis B v
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
